Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Kinome expression profiling to target new therapeutic avenues in multiple myeloma.

de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J.

Haematologica. 2019 Jul 9. pii: haematol.2018.208306. doi: 10.3324/haematol.2018.208306. [Epub ahead of print]

2.

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, De Raeve H, De Smedt E, Vlummens P, Szablewski V, Devin J, Faict S, De Veirman K, Menu E, Offner F, Spaargaren M, Moreaux J, Vanderkerken K, Van Valckenborgh E, De Bruyne E.

Br J Cancer. 2019 Jun;120(12):1137-1146. doi: 10.1038/s41416-019-0471-0. Epub 2019 May 15.

PMID:
31089208
3.

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.

De Smedt E, Lui H, Maes K, De Veirman K, Menu E, Vanderkerken K, De Bruyne E.

Front Oncol. 2018 Dec 11;8:566. doi: 10.3389/fonc.2018.00566. eCollection 2018. Review.

4.

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9.

PMID:
30419344
5.

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, Heusschen R, De Raeve H, Schots R, Vanderkerken K, Caers J, Menu E.

Blood Cancer J. 2018 Nov 8;8(11):105. doi: 10.1038/s41408-018-0139-7.

6.

The genetic landscape of 5T models for multiple myeloma.

Maes K, Boeckx B, Vlummens P, De Veirman K, Menu E, Vanderkerken K, Lambrechts D, De Bruyne E.

Sci Rep. 2018 Oct 9;8(1):15030. doi: 10.1038/s41598-018-33396-w.

7.

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.

De Beck L, Melhaoui S, De Veirman K, Menu E, De Bruyne E, Vanderkerken K, Breckpot K, Maes K.

Oncoimmunology. 2018 Jul 23;7(10):e1484981. doi: 10.1080/2162402X.2018.1484981. eCollection 2018.

8.

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C.

Oncotarget. 2018 Apr 27;9(32):22871. doi: 10.18632/oncotarget.25336. eCollection 2018 Apr 27.

9.

Metabolic Features of Multiple Myeloma.

El Arfani C, De Veirman K, Maes K, De Bruyne E, Menu E.

Int J Mol Sci. 2018 Apr 14;19(4). pii: E1200. doi: 10.3390/ijms19041200. Review.

10.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

11.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E.

Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.

12.

The therapeutic potential of cell cycle targeting in multiple myeloma.

Maes A, Menu E, Veirman K, Maes K, Vand Erkerken K, De Bruyne E.

Oncotarget. 2017 Jun 28;8(52):90501-90520. doi: 10.18632/oncotarget.18765. eCollection 2017 Oct 27. Review.

13.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.

14.

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C.

Oncotarget. 2017 May 24;8(32):52016-52025. doi: 10.18632/oncotarget.18152. eCollection 2017 Aug 8. Erratum in: Oncotarget. 2018 Apr 27;9(32):22871.

15.

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.

Favreau M, Menu E, Gaublomme D, Vanderkerken K, Faict S, Maes K, De Bruyne E, Govindarajan S, Drennan M, Van Calenbergh S, Leleu X, Zabeau L, Tavernier J, Venken K, Elewaut D.

Leukemia. 2017 Dec;31(12):2678-2685. doi: 10.1038/leu.2017.146. Epub 2017 May 11.

PMID:
28490813
16.

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition.

Favreau M, Venken K, Faict S, Maes K, De Veirman K, De Bruyne E, Leleu X, Boon L, Elewaut D, Vanderkerken K, Menu E.

Haematologica. 2017 Jul;102(7):e266-e270. doi: 10.3324/haematol.2017.163758. Epub 2017 Apr 6. No abstract available.

17.

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K.

J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30.

PMID:
27976373
18.

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.

Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, Garelli E, Mancini C, Lemmens H, Delforge M, Vandenberghe P, Wlodarska I, Aspesi A, Michaux L, Vanderkerken K, Sonneveld P, De Keersmaecker K.

Leukemia. 2017 Aug;31(8):1706-1714. doi: 10.1038/leu.2016.370. Epub 2016 Dec 2.

19.

Detection, isolation and characterization of Fusobacterium gastrosuis sp. nov. colonizing the stomach of pigs.

De Witte C, Flahou B, Ducatelle R, Smet A, De Bruyne E, Cnockaert M, Taminiau B, Daube G, Vandamme P, Haesebrouck F.

Syst Appl Microbiol. 2017 Jan;40(1):42-50. doi: 10.1016/j.syapm.2016.10.001. Epub 2016 Oct 24.

20.

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, Vanderkerken K, Menu E.

Oncotarget. 2016 Jun 21;7(25):38927-38945. doi: 10.18632/oncotarget.7792. Review.

21.

Comparative virulence of in vitro-cultured primate- and pig-associated Helicobacter suis strains in a BALB/c mouse and a Mongolian gerbil model.

Bosschem I, Flahou B, Bakker J, Heuvelman E, Langermans JA, De Bruyne E, Joosten M, Smet A, Ducatelle R, Haesebrouck F.

Helicobacter. 2017 Apr;22(2). doi: 10.1111/hel.12349. Epub 2016 Aug 24.

PMID:
27558281
22.

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken K, De Bruyne E.

Oncotarget. 2016 Jul 26;7(30):48732-48752. doi: 10.18632/oncotarget.8982. Review.

23.

Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.

Bieghs L, Brohus M, Kristensen IB, Abildgaard N, Bøgsted M, Johnsen HE, Conover CA, De Bruyne E, Vanderkerken K, Overgaard MT, Nyegaard M.

PLoS One. 2016 Apr 25;11(4):e0154256. doi: 10.1371/journal.pone.0154256. eCollection 2016.

24.

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I.

Cancer Lett. 2016 Jul 10;377(1):17-24. doi: 10.1016/j.canlet.2016.04.024. Epub 2016 Apr 19.

PMID:
27102001
25.

Evaluation of Exercise Performance, Cardiac Function, and Quality of Life in Children After Liver Transplantation.

Vandekerckhove K, Coomans I, De Bruyne E, De Groote K, Panzer J, De Wolf D, Boone J, De Bruyne R.

Transplantation. 2016 Jul;100(7):1525-31. doi: 10.1097/TP.0000000000001167.

PMID:
27014793
26.

Oral glutathione supplementation drastically reduces Helicobacter-induced gastric pathologies.

De Bruyne E, Ducatelle R, Foss D, Sanchez M, Joosten M, Zhang G, Smet A, Pasmans F, Haesebrouck F, Flahou B.

Sci Rep. 2016 Feb 2;6:20169. doi: 10.1038/srep20169.

27.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768.

28.

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Review.

29.

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E.

Oncotarget. 2015 Dec 22;6(41):43992-4004. doi: 10.18632/oncotarget.6083.

30.

Challenging factors for enuresis treatment: Psychological problems and non-adherence.

Van Herzeele C, De Bruyne P, De Bruyne E, Walle JV.

J Pediatr Urol. 2015 Dec;11(6):308-13. doi: 10.1016/j.jpurol.2015.04.035. Epub 2015 Jun 24. Review.

PMID:
26182849
31.

Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination.

Bosschem I, Bayry J, De Bruyne E, Van Deun K, Smet A, Vercauteren G, Ducatelle R, Haesebrouck F, Flahou B.

PLoS One. 2015 Jun 26;10(6):e0131364. doi: 10.1371/journal.pone.0131364. eCollection 2015.

32.

Role of γ-glutamyltranspeptidase in the pathogenesis of Helicobacter suis and Helicobacter pylori infections.

Zhang G, Ducatelle R, De Bruyne E, Joosten M, Bosschem I, Smet A, Haesebrouck F, Flahou B.

Vet Res. 2015 Mar 13;46:31. doi: 10.1186/s13567-015-0163-6.

33.

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.

De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2015 Apr 30;6(12):10532-47.

34.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E.

Oncotarget. 2015 Feb 20;6(5):3319-34.

35.

Purification of Helicobacter suis Strains From Biphasic Cultures by Single Colony Isolation: Influence on Strain Characteristics.

Liang J, De Bruyne E, Ducatelle R, Smet A, Haesebrouck F, Flahou B.

Helicobacter. 2015 Jun;20(3):206-16. doi: 10.1111/hel.12192. Epub 2015 Jan 12.

PMID:
25582323
36.

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA.

Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Review.

37.

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.

Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E.

Br J Haematol. 2014 Dec;167(5):651-63. doi: 10.1111/bjh.13092. Epub 2014 Aug 21.

PMID:
25142285
38.

Presence of Helicobacter suis on pork carcasses.

De Cooman L, Houf K, Smet A, Flahou B, Ducatelle R, De Bruyne E, Pasmans F, Haesebrouck F.

Int J Food Microbiol. 2014 Sep 18;187:73-6. doi: 10.1016/j.ijfoodmicro.2014.06.016. Epub 2014 Jul 3.

PMID:
25058686
39.

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.

Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 Nov 30;5(22):11193-208.

40.

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.

De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K.

Cancers (Basel). 2014 Jun 27;6(3):1363-81. doi: 10.3390/cancers6031363.

41.

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E.

Blood. 2014 Jul 24;124(4):555-66. doi: 10.1182/blood-2014-03-562439. Epub 2014 Jun 13.

42.

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.

Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 May 30;5(10):3115-29.

43.

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E.

Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430.

44.

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

Lemaire M, D'Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, Vanderkerken K.

Leukemia. 2014 Feb;28(2):444-7. doi: 10.1038/leu.2013.292. Epub 2013 Oct 9. No abstract available.

PMID:
24166214
45.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

46.

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E.

PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013.

47.

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K.

Dis Model Mech. 2012 Nov;5(6):763-71. doi: 10.1242/dmm.008961. Review.

48.

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.

Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K, Van Valckenborgh E.

Biochem Biophys Res Commun. 2012 Nov 30;428(4):518-24. doi: 10.1016/j.bbrc.2012.10.071. Epub 2012 Oct 27.

PMID:
23111325
49.

An experimental Helicobacter suis infection causes gastritis and reduced daily weight gain in pigs.

De Bruyne E, Flahou B, Chiers K, Meyns T, Kumar S, Vermoote M, Pasmans F, Millet S, Dewulf J, Haesebrouck F, Ducatelle R.

Vet Microbiol. 2012 Dec 7;160(3-4):449-54. doi: 10.1016/j.vetmic.2012.06.031. Epub 2012 Jun 27.

PMID:
22776514
50.

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow.

Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P, Vanderkerken K, Van Ginderachter JA.

Leukemia. 2012 Nov;26(11):2424-8. doi: 10.1038/leu.2012.113. Epub 2012 Apr 23. No abstract available.

PMID:
22522789

Supplemental Content

Loading ...
Support Center